These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. De Luca L; Capranzano P; Patti G; Parodi G Am Heart J; 2016 Jun; 176():44-52. PubMed ID: 27264219 [TBL] [Abstract][Full Text] [Related]
27. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S; JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445 [TBL] [Abstract][Full Text] [Related]
28. Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study. Bruno F; Wenzl FA; De Filippo O; Kraler S; Giacobbe F; Roffi M; Muller O; Räber L; Templin C; De Ferrari GM; D'Ascenzo F; Lüscher TF; Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):391-402. PubMed ID: 38604747 [TBL] [Abstract][Full Text] [Related]
29. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683 [TBL] [Abstract][Full Text] [Related]
30. Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy. Hamilos M; Petousis S; Xanthopoulou I; Goudevenos J; Kanakakis J; Sitafidis G; Vavouranakis M; Skalidis E; Kochiadakis G; Lekakis J; Vardas PE; Alexopoulos D Coron Artery Dis; 2018 Jan; 29(1):53-59. PubMed ID: 28834792 [TBL] [Abstract][Full Text] [Related]
31. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544 [TBL] [Abstract][Full Text] [Related]
32. Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). Saia F; Marino M; Campo G; Valgimigli M; Guastaroba P; Taglieri N; Tondi S; Manari A; Guiducci V; Sangiorgio P; Varani E; Magnavacchi P; De Palma R; Marzocchi A Am J Cardiol; 2013 Sep; 112(6):792-8. PubMed ID: 23747044 [TBL] [Abstract][Full Text] [Related]
33. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009 [TBL] [Abstract][Full Text] [Related]
34. The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review. Chandrasekhar J; Hibbert B; Froeschl M; So D; Mehran R; May ML; Eur J Clin Pharmacol; 2016 Jan; 72(1):83-91. PubMed ID: 26453463 [TBL] [Abstract][Full Text] [Related]
35. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Jiang M; You JH Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429 [TBL] [Abstract][Full Text] [Related]
36. New antiplatelet agents in the treatment of acute coronary syndromes. Sabouret P; Taiel-Sartral M Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752 [TBL] [Abstract][Full Text] [Related]
37. P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. Zeymer U; Widimsky P; Danchin N; Lettino M; Bardaji A; Barrabes JA; Cequier A; Claeys MJ; De Luca L; Dörler J; Erlinge D; Erne P; Goldstein P; Koul SM; Lemesle G; Lüscher TF; Matter CM; Montalescot G; Radovanovic D; Sendón JL; Tousek P; Weidinger F; Weston CF; Zaman A; Andell P; Li J; Jukema JW; Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):229-43. PubMed ID: 27533946 [TBL] [Abstract][Full Text] [Related]
38. Switching of Oral P2Y Carrillo-Aleman L; Marín F; Rivera-Caravaca JM; Vicente-Ibarra N; Candela-Sanchez E; Esteve-Pastor MA; Lozano T; Sandín-Rollan M; Pernias-Escrig V; Macías M; Quintana-Giner M; Veliz A; Orenes-Piñero E; Martínez-Martínez JG; Ruiz-Nodar JM Clin Drug Investig; 2019 Mar; 39(3):275-283. PubMed ID: 30623372 [TBL] [Abstract][Full Text] [Related]
39. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085 [TBL] [Abstract][Full Text] [Related]
40. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]